| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Anticancer agent 319 (compound 11e) (48-72 hours) effectively inhibited the proliferation of human liver cancer cells HepG2 and Hep3B, with IC50 values of 2.22 μM (72 hours, HepG2), 4.55 μM (48 hours, HepG2) and 4.95 μM (48 hours, Hep3B), respectively, but had no inhibitory effect on the proliferation of Huh-7 cells [1]. Anticancer agent 319 (2.5-10 μM; 24-48 hours) inhibited the migration of human liver cancer cell line HepG2 in a dose-dependent manner [1]. Anticancer drug 319 (2.5-10 μM; 36-48 hours) could induce G2/M phase cell cycle arrest in human liver cancer HepG2 cells, trigger concentration-dependent apoptosis, and reduce mitochondrial membrane potential [1]. The anticancer drug 319 (2.5-10 μM; 36 hours) can dose-dependently inhibit the phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204) and block the PI3K/AKT and MAPK/ERK signaling pathways in human hepatocellular carcinoma HepG2 cells [1].
|
|---|---|
| Cell Assay |
Cell migration assay [1]
Cell Types: Human hepatocellular carcinoma HepG2 Tested Concentrations: 2.5, 5 and 10 μM Incubation Duration: 24 hours; 48 hours Experimental Results: HepG2 cell migration was inhibited in a dose-dependent manner. After 48 hours, the wound healing rate decreased to 52.96% (2.5 μM), 27.41% (5 μM) and 13.45% (10 μM), respectively, while the control group was 59.11%. Cell cycle analysis [1] Cell Types: Human hepatocellular carcinoma cells HepG2 Tested Concentrations: 2.5, 5 and 10 μM Incubation Duration: 36 hours Experimental Results: All concentrations induced G2/M phase arrest. At concentrations of 5 μM and 10 μM, the proportion of SubG1 (apoptotic) cells increased to approximately 22.33%, indicating the presence of DNA fragmentation and apoptosis. Apoptosis Analysis [1] Cell Types: Human HepG2 liver cancer cells Tested Concentrations: 2.5, 5, and 10 μM Incubation Duration: 48 hours Experimental Results: Characteristic apoptotic nuclear changes, including nuclear condensation and karyorrhagia, were induced in a dose-dependent manner. Control cells showed uniform pale blue nuclear staining. The proportion of early and late apoptotic cells was increased in a concentration-dependent manner. This resulted in a significant reduction in the number of viable cells compared to the control group.
|
| References |
| Molecular Formula |
C33H34CL2N2O8
|
|---|---|
| Molecular Weight |
657.54
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
COC([C@@H](NC(CCC(OCCOC1=CC2=C(C3=CC=CC=C3C(O2)=O)C=C1)=O)=O)CC4=CC=C(C=C4)N(CCCl)CCCl)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5208 mL | 7.6041 mL | 15.2082 mL | |
| 5 mM | 0.3042 mL | 1.5208 mL | 3.0416 mL | |
| 10 mM | 0.1521 mL | 0.7604 mL | 1.5208 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
